Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/28
C07K-014/62
출원번호
US-0235381
(2002-09-05)
발명자
/ 주소
Soltero, Richard
Radhakrishan, Balasingam
Ekwuribe, Nnochiri N.
Rehlaender, Bruce
Hickey, Anthony
Bovet, Li Li
출원인 / 주소
Nobex Corporation
대리인 / 주소
Moore &
인용정보
피인용 횟수 :
21인용 특허 :
173
초록▼
Pharmaceutical compositions that include an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio o
Pharmaceutical compositions that include an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.
대표청구항▼
1. A pharmaceutical composition comprising:an insulin drug-oligomer conjugate comprising an insulin polypeptide covalently coupled to an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; A
1. A pharmaceutical composition comprising:an insulin drug-oligomer conjugate comprising an insulin polypeptide covalently coupled to an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; a fatty acid component comprising a fatty acid; and a bile salt component comprising a bile salt; wherein the fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1, wherein the fatty acid component is present in an amount sufficient to lower the precipitation point of the bile salt compared to a precipitation point of the bile salt if the fatty acid component were not present in the pharmaceutical composition, and wherein the bile salt component is present in an amount sufficient to lower the solubility point of the fatty acid compared to a solubility point of the fatty acid if the bile salt were not present in the pharmaceutical composition. 2. The pharmaceutical composition of claim 1, wherein the fatty acid component is present in an amount sufficient to lower the precipitation point of the bile salt by at least 1.0 pH units.3. The pharmaceutical composition of claim 1, wherein the bile salt component is present in an amount sufficient to lower the solubility point of the fatty acid by at least 0.5 pH units.4. The pharmaceutical composition of claim 1, wherein the bile salt component is present in an amount such that the fatty acid is soluble at a pH of 8.2, and wherein the fatty acid component is present in an amount such that the bile salt remains in solution at a pH of 5.5.5. The pharmaceutical composition of claim 1, wherein the fatty acid component and the bile salt component are present in a weight ratio of between 1:2 and 2:1.6. The pharmaceutical composition of claim 1, wherein the bile salt component comprises a pharmaceutically acceptable salt of cholic acid.7. The pharmaceutical composition of claim 1, wherein the bile salt component is sodium cholate.8. The pharmaceutical composition of claim 1, wherein the fatty acid component comprises a medium-chain fatty acid and a long-chain fatty acid.9. The pharmaceutical composition of claim 8, wherein the medium-chain fatty acid is selected from the group consisting of lauric acid, capric acid, and mixtures thereof, and the long-chain fatty acid is oleic acid.10. The pharmaceutical composition of claim 1, wherein the pH of the composition is between 6.2 and 9.0.11. The pharmaceutical composition of claim 1, further comprising a buffering component.12. The pharmaceutical composition of claim 11, wherein the buffering component comprises tris-base or trolamine.13. The pharmaceutical composition of claim 11, wherein the pharmaceutical composition is a liquid pharmaceutical composition.14. The pharmaceutical composition of claim 13, wherein the liquid pharmaceutical composition is suitable for oral administration.15. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a solid dosage pharmaceutical composition.16. The pharmaceutical composition of claim 1, wherein the insulin analog comprises lysine at the B29 position of the insulin analog and the oligomeric moiety is coupled to the B29 lysine.17. The pharmaceutical composition of claim 1, wherein the insulin drug-oligomer conjugate is present as a substantially monodispersed mixture.18. The pharmaceutical composition of claim 1, wherein the insulin drug-oligomer conjugate is present as a monodispersed mixture.19. The pharmaceutical composition of claim 1, wherein the insulin drug-oligomer conjugate is amphiphilically balanced.20. The pharmaceutical composition of claim 1, wherein the oligomeric moiety comprises a hydrophilic moiety and a lipophilic moiety.21. The pharmaceutical composition of claim 1, wherein the insulin drug-oligomer conjugate comprises the structure of Formula V: 22. A pharmaceutical composition comprising:an insulin drug-oligomer conjugate comprising an insulin polypeptide covalently coupled to an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; a bile salt component comprising a bile salt; and a fatty acid component comprising a fatty acid, wherein the fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1, and wherein the fatty acid component is present in a first amount such that, at the precipitation point of the bile salt, the bile salt precipitates as first bile salt particles that, upon a return to a pH above the precipitation point of the bile salt, re-solubilize more quickly than second bile salt particles that would have precipitated if the fatty acid component were not present in the composition. 23. The pharmaceutical composition of claim 22, wherein the precipitation point of the bile salt is at or below a pH of 5.5.24. The pharmaceutical composition of claim 22, wherein the first bile salt are able to re-solubilize in less than 75% of the time it would have taken for the second bile salt particles to re-solubilize.25. The pharmaceutical composition of claim 22, wherein the fatty acid component and the bile salt component are present in a weight ratio of between 1:2 and 2:1.26. The pharmaceutical composition of claim 22, wherein the bile salt component comprises a pharmaceutically acceptable salt of cholic acid.27. The pharmaceutical composition of claim 22, wherein the bile salt component is sodium cholate.28. The pharmaceutical composition of claim 22, wherein the fatty acid component comprises a medium-chain fatty acid and a long-chain fatty acid.29. The pharmaceutical composition of claim 28, wherein the medium-chain fatty acid is selected from the group consisting of lauric acid, capric acid, and mixtures thereof, and the long-chain fatty acid is oleic acid.30. The pharmaceutical composition of claim 22, wherein the pH of the composition is between 6.2 and 9.0.31. The pharmaceutical composition of claim 22, further comprising a buffering component.32. The pharmaceutical composition of claim 31, wherein the buffering component comprises tris-base or trolamine.33. The pharmaceutical composition of claim 31, wherein the pharmaceutical composition is a liquid pharmaceutical composition.34. The pharmaceutical composition of claim 33, wherein the liquid pharmaceutical composition is suitable for oral administration.35. The pharmaceutical composition of claim 33, wherein the liquid pharmaceutical composition is suitable for parenteral administration.36. The pharmaceutical composition of claim 22, wherein the pharmaceutical composition is a solid dosage pharmaceutical composition.37. The pharmaceutical composition of claim 22, wherein the insulin analog comprises lysine at the B29 position of the insulin analog and the oligomeric moiety is coupled to the B29 lysine.38. The pharmaceutical composition of claim 22, wherein the insulin drug-oligomer conjugate is present as a substantially monodispersed mixture.39. The pharmaceutical composition of claim 22, wherein the insulin drug-oligomer conjugate is present as a monodispersed mixture.40. The pharmaceutical composition of claim 22, wherein the insulin drug-oligomer conjugate is amphiphilically balanced.41. The pharmaceutical composition of claim 22, wherein the oligomeric moiety comprises a hydrophilic moiety and a lipophilic moiety.42. The pharmaceutical composition of claim 22, wherein the insulin drug-oligomer conjugate comprises the structure of Formula V: 43. A pharmaceutical composition comprising:an insulin drug-oligomer conjugate comprising an insulin polypeptide and an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; between 0.1 and 15% (w/v) of a fatty acid component; wherein the fatty acid component comprises a medium-chain fatty acid and a long-chain fatty acid; and between 0.1 and 15% (w/v) of a bile salt component; wherein the fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. 44. The pharmaceutical composition of claim 43, wherein the fatty acid component and the bile salt component are present in a weight ratio of between 1:2 and 2:1.45. The pharmaceutical composition of claim 43, wherein the bile salt component comprises a pharmaceutically acceptable salt of cholic acid.46. The pharmaceutical composition of claim 43, wherein the bile salt component is sodium cholate.47. The pharmaceutical composition of claim 43, wherein the medium-chain fatty acid is selected from the group consisting of lauric acid, capric acid, and mixtures thereof, and the long-chain fatty acid is oleic acid.48. The pharmaceutical composition of claim 43, wherein the pH of the composition is between 6.2 and 9.0.49. The pharmaceutical composition of claim 43, further comprising a buffering component.50. The pharmaceutical composition of claim 49, wherein the buffering component comprises tris-base or trolamine.51. The pharmaceutical composition of claim 49, wherein the pharmaceutical composition is a liquid pharmaceutical composition.52. The pharmaceutical composition of claim 51, wherein the liquid pharmaceutical composition is suitable for oral administration.53. The pharmaceutical composition of claim 51, wherein the liquid pharmaceutical composition is suitable for parenteral administration.54. The pharmaceutical composition of claim 43, wherein the pharmaceutical composition is a solid dosage pharmaceutical composition.55. The pharmaceutical composition of claim 43, wherein the insulin analog comprises lysine at the B29 position of the insulin analog and the oligomeric moiety is coupled to the B29 lysine.56. The pharmaceutical composition of claim 43, wherein the insulin drug-oligomer conjugate is present as a substantially monodispersed mixture.57. The pharmaceutical composition of claim 43, wherein the insulin drug-oligomer conjugate is present as a monodispersed mixture.58. The pharmaceutical composition of claim 43, wherein the insulin drug-oligomer conjugate is amphiphilically balanced.59. The pharmaceutical composition of claim 43, wherein the oligomeric moiety comprises a hydrophilic moiety and a lipophilic moiety.60. The pharmaceutical composition of claim 43, wherein the insulin drug-oligomer conjugate comprises the structure of Formula V: 61. A pharmaceutical composition comprising:an insulin drug-oligomer conjugate comprising the structure of Formula V: wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human and the oligomeric moiety of the conjugate is coupled to the B29 lysine of the insulin polypeptide; between 0.1 and 15% (w/v) of a fatty acid component comprising capric acid, lauric acid, and oleic acid; and between 0.1 and 15% (w/v) of a bile salt component comprising a pharmaceutically acceptable salt of cholic acid; wherein the fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. 62. A method of treating an insulin deficiency in a subject in need of such treatment, said method comprising administering to the subject a pharmaceutical composition comprising(a) a therapeutically effective amount of an insulin drug-oligomer conjugate that comprises an insulin polypeptide covalently coupled to an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; (b) a fatty acid component comprising a fatty acid; and (c) a bile salt component comprising a bile salt, wherein the fatty acid component and the bile salt component are present in a weight ratio of between 1:5 and 5:1, wherein the fatty acid component is present in an amount sufficient to lower the precipitation point of the bile salt compared to a precipitation point of the bile salt if the fatty acid component were not present in the pharmaceutical composition, and wherein the fatty acid component is present in an amount sufficient to lower the solubility point of the fatty acid compared to a solubility point of the fatty acid if the bile salt were not present in the pharmaceutical composition. 63. The method of claim 62, wherein the fatty acid component is present in an amount sufficient to lower the precipitation point of the bile salt by at least 1.0 pH units.64. The method of claim 62, wherein the bile salt component is present in an amount sufficient to lower the solubility point of the fatty acid by at least 0.5 pH units.65. The method of claim 62, wherein the bile salt component is present in an amount such that the fatty acid is soluble at a pH of 8.2, and wherein the fatty acid component is present in an amount such that the bile salt remains in solution at a pH of 5.5.66. The method of claim 62, wherein the fatty acid component and the bile salt component are present in a weight ratio of between 1:2 and 2:1.67. The method of claim 62, wherein the bile salt component comprises a pharmaceutically acceptable salt of cholic acid.68. The method of claim 62, wherein the bile salt component is sodium cholate.69. The method of claim 62, wherein the fatty acid component comprises a medium-chain fatty acid and a long-chain fatty acid.70. The method of claim 69, wherein the medium-chain fatty acid is selected from the group consisting of lauric acid, capric acid, and mixtures thereof, and the long-chain fatty acid is oleic acid.71. The method of claim 62, wherein the pH of the composition is between 6.2 and 9.0.72. The method of claim 62, further comprising a buffering component.73. The method of claim 72, wherein the buffering component comprises tris-base or trolamine.74. The method of claim 72, wherein the pharmaceutical composition is a liquid pharmaceutical composition.75. The method of claim 62, wherein the pharmaceutical composition is a solid dosage pharmaceutical composition.76. The method of claim 62, wherein the method comprises orally administering the pharmaceutical composition to the subject.77. The method of claim 62, wherein the insulin analog comprises lysine at the B29 position of the insulin analog and the oligomeric moiety is coupled to the B29 lysine.78. The method of claim 62, wherein the insulin drug-oligomer conjugate is present as a substantially monodispersed mixture.79. The method of claim 62, wherein the insulin drug-oligomer conjugate is present as a monodispersed mixture.80. The method of claim 62, wherein the insulin drug-oligomer conjugate is amphiphilically balanced.81. The method of claim 62, wherein the oligomeric moiety comprises a hydrophilic moiety and a lipophilic moiety.82. The method of claim 62, wherein the insulin drug-oligomer conjugate comprises the structure of Formula V: 83. A method of treating an insulin deficiency in a subject in need of such treatment, said method comprising administering to the subject a pharmaceutical composition comprising:(a) a therapeutically effective amount of an insulin drug-oligomer conjugate that comprises an insulin polypeptide covalently coupled to an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; (b) a bile salt component comprising a bile salt; and (c) a fatty acid component comprising a fatty acid, wherein the fatty acid component and the bile salt component are present in a weight ratio of between 1:5 and 5:1, and wherein the fatty acid component is present in a first amount such that, at the precipitation point of the bile salt, the bile salt precipitates as first bile salt particles that, upon a return to a pH above the precipitation point of the bile salt, re-solubilize more quickly than second bile salt particles that would have precipitated if the fatty acid component were not present in the composition. 84. The method of claim 83, wherein the precipitation point of the bile salt is at or below a pH of 5.5.85. The method of claim 83, wherein the first bile salt are able to re-solubilize in less than 75% of the time it would have taken for the second bile salt particles to re-solubilize.86. The method of claim 83, wherein the fatty acid component and the bile salt component are present in a weight ratio of between 1:2 and 2:1.87. The method of claim 83, wherein the bile salt component comprises a pharmaceutically acceptable salt of cholic acid.88. The method of claim 83, wherein the bile salt component is sodium cholate.89. The method of claim 83, wherein the fatty acid component comprises a medium-chain fatty acid and a long-chain fatty acid.90. The method of claim 89, wherein the medium-chain fatty acid is selected from the group consisting of lauric acid, capric acid, and mixtures thereof, and the long-chain fatty acid is oleic acid.91. The method of claim 83, wherein the pH of the composition is between 6.2 and 9.0.92. The method of claim 83, further comprising a buffering component.93. The method of claim 92, wherein the buffering component comprises tris-base or trolamine.94. The method of claim 83, wherein the pharmaceutical composition is a liquid pharmaceutical composition.95. The method of claim 83, wherein the pharmaceutical composition is a solid dosage pharmaceutical composition.96. The method of claim 83, wherein the method comprises orally administering the pharmaceutical composition to the subject.97. The method of claim 83, wherein the insulin analog comprises lysine at the B29 position of the insulin analog and the oligomeric moiety is coupled to the B29 lysine.98. The method of claim 83, wherein the insulin drug-oligomer conjugate is present as a substantially monodispersed mixture.99. The method of claim 83, wherein the insulin drug-oligomer conjugate is present as a monodispersed mixture.100. The method of claim 83, wherein the insulin drug-oligomer conjugate is amphiphilically balanced.101. The method of claim 83, wherein the oligomeric moiety comprises a hydrophilic moiety and a lipophilic moiety.102. The method of claim 83, wherein the insulin drug-oligomer conjugate comprises the structure of Formula V: 103. A method of treating an insulin deficiency in a subject in need of such treatment, said method comprising administering to the subject a pharmaceutical composition comprising:(a) a therapeutically effective amount of an insulin drug-oligomer conjugate that comprises an insulin polypeptide and an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; (b) between 0.1 and 15% (w/v) of a fatty acid component comprises a medium-chain fatty acid and a long-chain fatty acid; and (c) between 0.1 and 15% (w/v) of a bile salt component, wherein the fatty acid component and the bile salt component are present in a weight to weight ratio of between 1:5 and 5:1. 104. The method of claim 103, wherein the fatty acid component and the bile salt component are present in a weight ratio of between 1:2 and 2:1.105. The method of claim 103, wherein the bile salt component comprises a pharmaceutically acceptable salt of cholic acid.106. The method of claim 103, wherein the bile salt component is sodium cholate.107. The method of claim 103, wherein the medium-chain fatty acid is selected from the group consisting of lauric acid, capric acid, and mixtures thereof, and the long-chain fatty acid is oleic acid.108. The method of claim 103, wherein the pH of the composition is between 6.2 and 9.0.109. The method of claim 103, further comprising a buffering component.110. The method of claim 109, wherein the buffering component comprises tris-base or trolamine.111. The method of claim 109, wherein the pharmaceutical composition is a liquid pharmaceutical composition.112. The method of claim 103, wherein the pharmaceutical composition is a solid dosage pharmaceutical composition.113. The method of claim 103, wherein the method comprises orally administering the pharmaceutical composition to the subject.114. The method of claim 103, wherein the insulin analog comprises lysine at the B29 position of the insulin analog and the oligomeric moiety is coupled to the B29 lysine.115. The method of claim 103, wherein the insulin drug-oligomer conjugate is present as a substantially monodispersed mixture.116. The method of claim 103, wherein the insulin drug-oligomer conjugate is present as a monodispersed mixture.117. The method of claim 103, wherein the insulin drug-oligomer conjugate is amphiphilically balanced.118. The method of claim 103, wherein the oligomeric moiety comprises a hydrophilic moiety and a lipophilic moiety.119. The method of claim 103, wherein the insulin drug-oligomer conjugate comprises the structure of Formula V: 120. A pharmaceutical composition comprising:an insulin drug-oligomer conjugate comprising an insulin polypeptide and an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; between 0.1 and 15% (w/v) of a fatty acid component; and between 0.1 and 15% (w/v) of a bile salt component; wherein the fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1, and wherein the pharmaceutical composition comprises a buffering component that comprises tris-base or trolamine. 121. The pharmaceutical composition of claim 120, wherein the pharmaceutical composition is a liquid pharmaceutical composition suitable for oral administration.122. The pharmaceutical composition of claim 120, wherein the pharmaceutical composition is a liquid pharmaceutical composition suitable for parenteral administration.123. The pharmaceutical composition of claim 120, wherein the pharmaceutical composition is a solid dosage pharmaceutical composition.124. A pharmaceutical composition comprising:an insulin drug-oligomer conjugate comprising an insulin polypeptide and an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; between 0.1 and 15% (w/v) of a fatty acid component; and between 0.1 and 15% (w/v) of a bile salt component; wherein the fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1, and wherein the insulin drug-oligomer conjugate is present as a monodispersed mixture. 125. A pharmaceutical composition comprising:an insulin drug-oligomer conjugate comprising an insulin polypeptide and an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; between 0.1 and 15% (w/v) of a fatty acid component; and between 0.1 and 15% (w/v) of a bile salt component; wherein the fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1, and wherein the insulin drug-oligomer conjugate is present as a monodispersed mixture. 126. A pharmaceutical composition comprising:an insulin drug-oligomer conjugate comprising an insulin polypeptide and an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; between 0.1 and 15% (w/v) of a fatty acid component; and between 0.1 and 15% (w/v) of a bile salt component; wherein the fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1, and wherein the insulin drug-oligomer conjugate comprises the structure of Formula V: 127. A method of treating an insulin deficiency in a subject in need of such treatment, said method comprising administering to the subject a pharmaceutical composition comprising: (a) a therapeutically effective amount of an insulin drug-oligomer conjugate that comprises an insulin polypeptide and an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human;between 0.1 and 15% (w/v) of a fatty acid component; and (c) between 0.1 and 15% (w/v) of a bile salt component, wherein the fatty acid component and the bile salt component are present in a weight to weight ratio of between 1:5 and 5:1, and wherein the pharmaceutical composition comprises a buffering component that comprises tris-base or trolamine. 128. The method of claim 127, wherein the pharmaceutical composition is a liquid pharmaceutical composition suitable for oral administration.129. The method of claim 127, wherein the pharmaceutical composition is a liquid pharmaceutical composition suitable for parenteral administration.130. The method of claim 127, wherein the pharmaceutical composition is a solid dosage pharmaceutical composition.131. A method of treating an insulin deficiency in a subject in need of such treatment, said method comprising administering to the subject a pharmaceutical composition comprising:(a) a therapeutically effective amount of an insulin drug-oligomer conjugate that comprises an insulin polypeptide and an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; (b) between 0.1 and 15% (w/v) of a fatty acid component; and (c) between 0.1 and 15% (w/v) of a bile salt component, wherein the fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1, and wherein the insulin drug-oligomer conjugate is present as a substantially monodispersed mixture. 132. A method of treating an insulin deficiency in a subject in need of such treatment, said method comprising administering to the subject a pharmaceutical composition comprising:(a) a therapeutically effective amount of an insulin drug-oligomer conjugate that comprises an insulin polypeptide and an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; (b) between 0.1 and 15% (w/v) of a fatty acid component; and (c) between 0.1 and 15% (w/v) of a bile salt component, wherein the fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1, and wherein the insulin drug-oligomer conjugate is present as a monodispersed mixture. 133. A method of treating an insulin deficiency in a subject in need of such treatment, said method comprising administering to the subject a pharmaceutical composition comprising:(a) a therapeutically effective amount of an insulin drug-oligomer conjugate that comprises an insulin polypeptide and an oligomeric moiety, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; AlaB28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 ProB29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human; (b) between 0.1 and 15% (w/v) of a fatty acid component; and (c) between 0.1 and 15% (w/v) of a bile salt component, wherein the fatty acid component and the bile salt component are present in a weight to weight ratio of between 1:5 and 5:1, and wherein the insulin drug-oligomer conjugate comprises the structure of Formula V:
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (173)
Greenwald Richard B. ; Gilbert Carl W., .alpha.-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same.
Belagaje Rama M. (Indianapolis IN) DiMarchi Richard D. (Carmel IN) Heath ; Jr. William F. (Indianapolis IN) Long Harlan B. (Carmel IN), A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production.
Kitao Kazuhiko (Kyoto JPX) Nishimura Ken-ichi (Kyoto JPX), Adjuvant for promoting absorption of pharmacologically active substances through the rectum.
Speaker Tully J. (Philadelphia PA) Speaker Tycho J. (Philadelphia PA) Collett John H. (Sale GB2), Adjuvant-enhanced sustained release composition and method for making.
Vanlerberghe Guy (Commune de Villevaude FRX) Handjani Rose-Marie (Paris FRX), Aqueous dispersions of lipid spheres and compositions containing the same.
Veronese Francesco (Padua ITX) Sartore Luciana (Padua ITX) Orsolini Piero (Martigny CHX) Deghenghi Romano (S.-Cergue CHX), Biologically active drug polymer derivatives and method for preparing same.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Biologically inert, biocompatible-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates containing an ether linkage.
Mill Patrick James (Beaconfield EN) Cresswell Michael Alan (High Wycombe EN) Feinberg Joseph George (London EN), Conjugates of acid polysaccharides and complex organic substances.
Saifer Mark (Berkeley CA) Somack Ralph (Oakland CA) Williams L. David (Fremont CA), Conjugates of superoxide dismutage coupled to high molecular weight polyalkylene glycols.
Ekwuribe Nnochiri N. (Southfield MI), Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and m.
Ekwuribe Nnochiri N. (Southfield MI), Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and m.
Huper Fritz (Wuppertal DT) Rauenbusch Erich (Wuppertal DT) Schmidt-Kastner Gunter (Wuppertal DT) Bomer Bruno (Leverkusen DT) Bartl Herbert (Odenthal-Hahnenberg DT), Crosslinked copolymers of ab
상세보기
Greenwald Richard B. (Somerset NJ) Martinez Anthony J. (Hamilton Square NJ), Cyclic imide thione activated polyalkylene oxides.
Shorr Robert G. L. (Edison NJ) Cho Myung-Ok P. (Highland Park NJ) Nho Kwang (Somerset NJ), Fractionation of polyalkylene oxide-conjugated hemoglobin solutions.
Buckley Douglas I. (215 Brookward Rd. Woodside CA 94062) Habener Joel F. (217 Plymouth Rd. Newton Highlands MA 02161) Mallory Joanne B. (199 Acalanes ; Apt. 3 Sunnyvale CA 94086) Mojsov Svetlana (504, GLP-1 analogs useful for diabetes treatment.
Kahne Daniel Evan (Princeton NJ) Kahne Suzanne Walker (Princeton NJ), Glycosylated steroid derivatives for transport across biological membranes and process for making and using same.
Newhouse Stanley (206 Juniper Cir. North Lawrence NY 11559) Lerner Robert (315 E. 65th St. New York NY 10021) Martin Roy (3312 182nd Pl. ; NE. Redmond WA 98452), Insulin delivery method and apparatus.
Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
Phillips Christopher P. (Brandamore PA) Snow Robert A. (West Chester PA), Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life.
Phillips Christopher P. (Brandamore PA) Snow Robert A. (West Chester PA), Lyophilized polyethylene oxide modified protein and polypeptide complexes with cyclodextrin.
Sutton Peter M. (Manderley GB2) Atkinson Anthony (Twingley GB2) Lloyd Graham (East Gomeldon GB2), Method and composition for the treatment and prevention of viral infections.
Brownlee Michael (Watertown MA) Cerami Anthony (Flanders NJ), Method and system for the controlled release of biologically active substances to a body fluid.
Brownlee Michael (Watertown MA) Cerami Anthony (Flanders NJ), Method and system for the controlled release of biologically active substances to a body fluid.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Method of preparing collagen-polymer conjugates.
Weiner Howard L. ; Eisenbarth George ; Hafler David Allen ; Zhang Zhengi, Method of treating or preventing Type 1 diabetes by oral administration of insulin.
Weiner Howard L. ; Eisenberth George ; Hafler David Allen ; Zhang Zhengi, Method of treating or preventing type 1 diabetes by oral administration of insulin.
Phillips William T. (San Antonio TX) Schwartz Joyce G. (San Antonio TX) Green Gary M. (San Antonio TX), Methods of normalizing metabolic parameters in diabetics.
Harris J. Milton ; Veronese Francesco Maria,ITX ; Caliceti Paolo,ITX ; Schiavon Oddone,ITX, Multiarmed, monofunctional, polymer for coupling to molecules and surfaces.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Henry R. Jones GB; Fariba Shojaee-Moradi GB; Peter Henri Sonksen GB; Dietrich Brandenburg DE; Achim Schuttler DE; Heike Eckey DE; Erik Sundermann DE, Pharmaceutical active conjugates.
Penkler Lawrence John,ZAX ; De Kock Lueta-Ann,ZAX ; Whittaker Darryl Vanstone,ZAX, Pharmaceutical composition containing acid addition salt of basic drug.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Polymer conjugates ophthalmic devices comprising collagen-polymer conjugates.
Nitecki Danute E. (Berkeley CA) Katre Nandini (El Cerrito CA) Goodson Robert J. (Albany CA) Aldwin Lois (San Mateo CA), Preparation of a polymer/interleukin-2 conjugate.
Baker Jeffrey Clayton (Indianapolis IN) Moser Brian A. (Indianapolis IN) Shrader Warren E. (Indianapolis IN), Preparation of an acylated protein powder.
Baker Jeffrey C. (Indianapolis IN) Carter Nancy D. (Indianapolis IN) Frank Bruce H. (Indianapolis IN), Preparation of stable zinc insulin analog crystals.
Delgado Cristina (London GBX) Francis Gillian E. (London GBX) Fisher Derek (London GBX), Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage col.
Appelgren Curt H. (Kungsbacka SEX) Eskilsson Eva C. (Mlnlycke SEX) Uvdal Jonas P. (Gothenburg SEX), Process for preparing rapidly disintegrating granulates.
Maitra Amarnath,INX ; Ghosh Prashant Kumar,INX ; De Tapas K.,INX ; Sahoo Sanjeeb Kumar,INX, Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles.
Mueller Herbert (Frankenthal DEX) Jeschek Gerhard (Gruenstadt DEX) Fischer Rolf (Heidelberg DEX) Weyer Hans-Juergen (Mannheim DEX), Process for the preparation of polyether glycols.
Frank Bruce H. (Indianapolis IN) Prouty Walker E. (Indianapolis IN) Heiney Richard E. (Greenwood IN) Walden Mark R. (Indianapolis IN), Process for transforming a human insulin precursor to human insulin.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Processes for preparing compositions for inhalation.
Eckenhoff James B. (Los Altos CA) Cortese Richard (Los Gatos CA) Landrau Felix A. (Milpitas CA), Rate controlled dispenser for administering beneficial agent.
Baker Jeffrey C. (Indianapolis IN) Hanquier Jose M. (Martinsville IN) Shrader Warren E. (Indianapolis IN), Reducing gelation of a fatty acid-acylated protein.
Baker Jeffrey C. (Indianapolis IN) Chen Victor J. (Indianapolis IN) Hanquier Jose M. (Martinsville IN) Kriauciunas Aidas (Indianapolis IN) Moser Brian A. (Indianapolis IN) Shuman Robert T. (Greenwood, Selective acylation of epsilon-amino groups.
Mensi-Fattohi Nahla (151 Rutgers Rd. Piscataway NJ 08854) Molineaux Christopher J. (115 E. 9th St. New York NY 10003) Shorr Robert G. L. (28 Brookfall Rd. Edison NJ 08820), Site specific synthesis of conjugated peptides.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Systemic administration of a therapeutic preparation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Systemic administration of a therapeutic preparation.
Backstrom Kjell Goran Erik (Lund SEX) Dahlback Carl Magnus Olof (Lund SEX) Edman Peter (Bjarred SEX) Johansson Ann Charlotte Birgit (Lund SEX), Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Longenecker John P. (Mountain View CA) Ennis Richard (Fremont CA) Baldwin Patricia A. (Hayward CA) Lee William A. (Los Altos CA), Transmembrane formulations for drug administration.
Havelund, Svend; Jensen, Simon Bjerregaard, Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein.
Ekwuribe,Nnochiri N.; Price,Christopher H.; Ansari,Aslam M.; Radhakrishnan,Balasingam; Odenbaugh,Amy L., Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.